Hancock Whitney Corp Catalyst Pharmaceuticals, Inc. Transaction History
Hancock Whitney Corp
- $5.11 Billion
- Q2 2025
A detailed history of Hancock Whitney Corp transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Hancock Whitney Corp holds 38,285 shares of CPRX stock, worth $778,716. This represents 0.02% of its overall portfolio holdings.
Number of Shares
38,285
Previous 38,847
1.45%
Holding current value
$778,716
Previous $942,000
11.89%
% of portfolio
0.02%
Previous 0.03%
Shares
20 transactions
Others Institutions Holding CPRX
# of Institutions
385Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$380 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$178 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$111 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$66.1 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$64.8 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.09B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...